IGF-1 LR3 — compound monograph
Recombinant insulin-like growth factor 1 analogue. Unapproved, research supply. The Institute assesses 2 outcomes for this compound and grades the strongest at very low certainty.
§1Identification and status
§1.1Nomenclature
- Preferred name
- IGF-1 LR3
- Compound class
- Recombinant insulin-like growth factor 1 analogue
- Assessment series
- Growth-hormone axis
- Synonyms and codes
- Long R3 IGF-1 · LR3 IGF-1 · IGF-1 Long Arg3
- Route as evaluated
- Subcutaneous in research contexts
§1.2Chemistry
Chemical identifiers are reproduced where they are public. Where a structure has not been published the monograph records not disclosed rather than constructing one.[1]
- CAS registry number
- 946870-92-4
- Molecular formula
- not applicable (recombinant protein)
- Average mass
- ≈9111 Da
- Monoisotopic mass
- not applicable
- ATC classification
- not assigned
§1.3Sequence and structural notes
The arginine-3 substitution markedly reduces affinity for IGF-binding proteins, and the N-terminal extension further extends circulating half-life. It is a recombinant protein expressed in bacterial culture, not a synthetic peptide, and it is frequently misrepresented as the latter.
§1.4Assessment status
The Institute assesses IGF-1 LR3 across 2 indications and grades the strongest of them at very low certainty. Supplied as a research chemical; no marketing authorisation for the uses under which it is supplied.
Table 1. Assessed outcomes for IGF-1 LR3, ordered by certainty. Each row links to the per-indication evidence extract.
| Indication | Effect as recorded | Certainty | Trials |
|---|---|---|---|
| Growth hormone deficiency and growth-hormone secretagogue pharmacology | No randomised human evidence identified for this analogue | Very low | 0 |
| Sarcopenia and lean-mass preservation during weight reduction | No randomised human evidence identified for this analogue | Very low | 0 |
| Effects are reproduced as the contributing trials reported them. Where a confidence interval is held it appears on the per-indication extract rather than in this summary table. | |||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.